Introduction
This analysis examines the historical and forecast performance for King in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to purchase this research
- Benchmark King's performance against key rivals in the ethical pharmaceutical sector
- See how King's future depends on the success of its launch portfolio following the patent expiry of several of the company's key products